Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate-Reference-Cited by-同舟云学术

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

Published:2006 Issue:9 Volume:54 Page:2817-2829
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Maini R. N.,Taylor P. C.,Szechinski J.,Pavelka K.,Bröll J.,Balint G.,Emery P.,Raemen F.,Petersen J.,Smolen J.,Thomson D.,Kishimoto T.,

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference36 articles.

1. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis

2. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides

3. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis.

4. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity.

5. Interleukin 6 and its Receptor: Ten Years Later

Cited by 664 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Newer Immunosuppressants for Rheumatologic Disease;Rheumatic Disease Clinics of North America;2024-08

2. The autoimmune landscape of Porto-sinusoidal vascular disorder: What the rheumatologist needs to know;Seminars in Arthritis and Rheumatism;2024-08

3. γδT Cells Induce the Inflammatory Response of Human Fibroblast-Like Synoviocytes Directly or by Stimulating B Cells to Activate IL-17/STAT3 Signaling Pathway;International Archives of Allergy and Immunology;2024-07-11

4. Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development;Expert Opinion on Investigational Drugs;2024-07-09

5. Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease;Annals of the Rheumatic Diseases;2024-07-04